NASDAQ:GBT
Delisted
GLOBAL BLOOD THERAPEUTICS Stock News
$68.49
+0 (+0%)
At Close: Jan 27, 2023
3 Biopharmas on Buyout Watch
12:00pm, Monday, 22'nd Aug 2022 The Motley Fool
These three biotech companies could be headed for a buyout soon.
Has Moderna Made a Bear Market Blunder?
01:15pm, Wednesday, 17'th Aug 2022 The Motley Fool
The company has stood pat while other businesses have been busy with M&A.
Pharma Stock Roundup: PFE to Buy GBT, JNJ to Stall Baby Talc Sale Globally From 2023
01:50pm, Friday, 12'th Aug 2022 Zacks Investment Research
Pfizer (PFE) offers to buy Global Blood Therapeutics (GBT) for $5.4 billion in cash. J&J (JNJ) to discontinue selling talc-based baby powder globally from 2023.
Get ready for more merger mania in the pharma sector for the rest of the year
11:30am, Thursday, 11'th Aug 2022 MarketWatch
Pfizer’s $5.4 billion acquisition of Global Blood Therapeutics is the latest sign that cash-flush drug makers are ready to make some deals.
Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US
07:26pm, Tuesday, 09'th Aug 2022 Benzinga
Barclays says that CRISPR Therapeutics AG's (NASDAQ: CRSP) Q2 FY22 earnings release was largely incremental, highlighting the progress of multiple clinical programs, including the goal of on-tra
8 Analysts Have This to Say About Global Blood Therapeutics
03:13pm, Tuesday, 09'th Aug 2022 Benzinga
Within the last quarter, Global Blood Therapeutics (NASDAQ:GBT) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
0
7
Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings
03:02pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for revenues in the second quarter of 2022.
Get ready for more merger mania in pharma sector the rest of the year
02:43pm, Tuesday, 09'th Aug 2022
Pfizer Inc.'s PFE, +0.24% $5.4 billion acquisition of Global Blood Therapeutics Inc. GBT, +0.02% is the latest sign that cash-flush drug makers are ready to jump back into dealmaking.
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022
02:13pm, Tuesday, 09'th Aug 2022 Benzinga
Upgrades
For Nutrien Ltd (NYSE:NTR), Scotiabank upgraded the previous rating of Sector Perform to Sector Outperform. Nutrien earned $5.85 in the second quarter, compared to $2.08 in the year-ago quar
Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings
12:47pm, Tuesday, 09'th Aug 2022
Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for revenues in the second quarter of 2022.
Where Global Blood Therapeutics Stands With Analysts
12:16pm, Tuesday, 09'th Aug 2022 Benzinga
Within the last quarter, Global Blood Therapeutics (NASDAQ:GBT) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
0
7
Pfizer is acquiring Global Blood Therapeutics
11:49am, Tuesday, 09'th Aug 2022
Pfizer Inc (NYSE: PFE) has executed a definitive merger agreement with Global Blood Therapeutics Inc (NASDAQ: GBT), whereby Pfizer will acquire the biopharmaceutical corporation dedicated to the de
Pfizer to buy Global Blood Therapeutics for US$5.4bn
06:18am, Tuesday, 09'th Aug 2022
Pfizer Inc (NYSE:PFE) is to pay US$5.4bn in cash to acquire sickle cell disease drugmaker Global Blood Therapeutics, Inc (NASDAQ:GBT) (GBT) as the pharma major looks to leverage the booming revenue
Why Global Blood Therapeutics Stock Was Trouncing the Market Today
06:51pm, Monday, 08'th Aug 2022 The Motley Fool
The blood-disorder specialist sells itself in a deal with an enterprise value of around $5.4 billion.
Why These Pfizer Analysts Like The Global Blood Therapeutics Deal
06:50pm, Monday, 08'th Aug 2022 Benzinga
Pfizer Inc. (NYSE: PFE) shares were trading lower Monday after the drugmaker announced a $5.4-billion bid to acquire blood disorder drugmaker Global Blood Therapeutics Inc (NASDAQ: GBT).
Pfizer said i
